KLRS

Kalaris Therapeutics Inc

2.00

Nov 02 • 3:59 PM ET -0.03 (-1.48%)

2.00

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: OTLK KOD EYPT OCUL FDMT RGNX REGN IRD OCGN OKYO

| Held by: VTI VXF IWC BUSM DCOR DXUV DFAC

Scroll to Statements

Index	-
Market Cap	43.68M
Enterprise Value	-48.46M
Income	-44.26M
Sales	0.00M
Book/sh	2.42
Cash/sh	4.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	20
IPO	Jul 30, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.83
P/C	0.47
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.92
Current Ratio	10.92
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-2.01
EPS next Y	-1.65
EPS next Q	-0.52
EPS this Y	29.78%
EPS next Y	17.43%
EPS next 5Y	5.48%
EPS past 3/5Y	61.69% 45.59%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.44%
Sales Y/Y TTM	-
EPS Q/Q	20.27%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	3.03% -

Insider Own	63.69%
Insider Trans	1.79%
Inst Own	25.47%
Inst Trans	-2.35%
ROA	-46.02%
ROE	-79.91%
ROIC	-75.37%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.06%
SMA50	-31.14%
SMA200	-62.76%
Trades

Shs Outstand	23.80M
Shs Float	8.64M
Short Float	3.55%
Short Ratio	4.45
Short Interest	0.31M
52W High	11.88 -83.16%
52W Low	1.78 12.36%
Volatility	6.39% 8.42%
ATR (14)	0.17
RSI (14)	35.85
Beta	0.46
Rel Volume	0.86
Avg Volume	68.81K
Volume	59,274

Perf Week	11.11%
Perf Month	-25.93%
Perf Quarter	-53.70%
Perf Half Y	-63.83%
Perf YTD	-76.30%
Perf Year	-60.24%
Perf 3Y	-95.03%
Perf 5Y	-99.62%
Perf 10Y	-
Recom	1.25
Target Price	17.67
Prev Close	2.03
Price	2.00
Change %	-1.48%

Consensus

Strong Buy

Avg. Price Target

$17.67

Implied Upside

+783.5%

Analysts9incl. previous ratings

Rating Distribution8 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 15, 2026	Initiated	TTD Cowen	Buy
May 14, 2026	Initiated	WWedbush	Outperform	$17	+750.0%
Apr 16, 2026	Initiated	MMorgan Stanley	Overweight	$14	+600.0%
Dec 23, 2025	Initiated	CChardan Capital Markets	Buy	$19	+850.0%
Nov 03, 2025	Initiated	CCitizens JMP	Mkt Outperform	$20	+900.0%
Sep 03, 2025	Initiated	RRaymond James	Strong Buy	$23	+1,050.0%
Jul 23, 2025	Resumed	PPiper Sandler	Neutral	$3	+50.0%
May 07, 2025	Initiated	LLeerink Partners	Outperform	$20	+900.0%
Apr 08, 2025	Initiated	WWilliam Blair	Outperform

Aug-31-26 08:00AM	Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-26 08:00AM	Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-20-26 08:00AM	Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer (GlobeNewswire) -8.68%
Jul-17-26 07:00AM	Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts (GlobeNewswire)
Jul-06-26 04:05PM	Kalaris Appoints Laurie Keating to Board of Directors (GlobeNewswire)
08:00AM	Loading…
Jun-23-26 08:00AM	Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling (GlobeNewswire)
Jun-12-26 08:00AM	Kalaris to Present at Clinical Trials at the Summit 2026 (GlobeNewswire)
May-14-26 09:45AM	Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly) +8.07%
May-12-26 08:00AM	Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jan-28-26 04:05PM	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting (GlobeNewswire)
Dec-17-25 05:59PM	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement (GlobeNewswire) +20.32%
04:01PM	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD (GlobeNewswire)
Nov-24-25 08:00AM	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (Newsfile) -7.99%
Nov-12-25 08:00AM	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 07:30AM	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer (GlobeNewswire)
08:00AM	Loading…
Oct-30-25 08:00AM	Kalaris to Present at Stifel 2025 Annual Healthcare Conference (GlobeNewswire)
Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	May 20 '26	Buy	4.83	244,300	1,179,969	2,224,147	May 22 07:47 PM
Hagen Brett R	Chief Accounting Officer	Mar 20 '26	Sale	6.72	1,915	12,869	0	Mar 23 04:05 PM
BRETT R R HAGEN	Officer	Mar 20 '26	Proposed Sale	6.72	1,915	12,869		Mar 20 04:07 PM
AKKARAJU SRINIVAS	Director	Dec 18 '25	Buy	10.42	479,847	5,000,006	1,979,847	Feb 17 08:15 PM

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.

PresidentMr. Andrew Oxtoby

Ph.D.Dr. Srinivas Akkaraju M.D.

Co-Founder & DirectorDr. Michael Philip Dybbs Ph.D.

Independent Director & Co-FounderDr. Napoleone Ferrara M.D.

Chief Medical OfficerDr. Matthew Feinsod M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRS

Kalaris Therapeutics Inc

Upgrade your Finviz experience